cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Karyopharm Therapeutics Inc
15 own
21 watching
Current Price
$1.21
$0.06
(4.78%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
234.91M
52-Week High
52-Week High
6.01000
52-Week Low
52-Week Low
1.11000
Average Volume
Average Volume
0.89M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
21.0465
iconMarket Capitalization234.91M
icon52-Week High6.01000
icon52-Week Low1.11000
iconAverage Volume0.89M
iconDividend Yield--
iconP/E Ratio21.0465
What does the Karyopharm Therapeutics Inc do?
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Read More
How much money does Karyopharm Therapeutics Inc make?
News & Events about Karyopharm Therapeutics Inc.
Zolmax
3 months ago
Karyopharm Therapeutics (NASDAQ:KPTI Get Rating) and Gracell Biotechnologies (NASDAQ:GRCL Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ...
PR Newswire
4 months ago
Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent...
PR Newswire
5 months ago
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Nave Myelofibrosis at AACR 2023 Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Nave Myelofibrosis at AACR 2023 PR Newswire NEWTON, Mass., April 18, 2023 At...
PR Newswire
5 months ago
Karyopharm To Present Data from Phase 1 Study of Selinexor in Patients with Treatment-Nave Myelofibrosis at AACR and to Host Investor Webcast on April 18th Karyopharm To Present Data from Phase 1 Study of Selinexor in Patients with Treatment-Nave Myelofibrosis at AACR and to Host Investor Webcast...
PR Newswire
7 months ago
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One...
Frequently Asked Questions
Frequently Asked Questions
What is Karyopharm Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Karyopharm Therapeutics Inc shares?
plus_minus_icon
How can I buy Karyopharm Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Karyopharm Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Karyopharm Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Karyopharm Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Karyopharm Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Karyopharm Therapeutics Inc?
plus_minus_icon
What percentage is Karyopharm Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Karyopharm Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.21
$0.06
(4.78%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Mesoblast
Mesoblast
$1.20
$-0.04 (-3.23 %)
ADT Corp., The
ADT Corp., The
$5.90
$-0.02 (-0.34 %)
TREDEGAR CORP
TREDEGAR CORP
$5.20
$0.01 (0.29 %)
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
$1.64
$-0.15 (-8.38 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Mesoblast
Mesoblast
$1.20
$-0.04 (-3.23 %)
ADT Corp., The
ADT Corp., The
$5.90
$-0.02 (-0.34 %)
TREDEGAR CORP
TREDEGAR CORP
$5.20
$0.01 (0.29 %)
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
$1.64
$-0.15 (-8.38 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00